All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld Perspectives » Balancing innovation and access: The policy conundrum

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Balancing innovation and access: The policy conundrum

Sep. 15, 2014
By Jennifer Boggs
No Comments

Blog 9-15-14RIO DE JANEIRO – I was in college when I first read Ayn Rand’s Atlas Shrugged. Safe within the privileged and idealistic bubble of academia, I found myself agreeing with Rand at every turn, filled with the pro-capitalist and individualist spirit.  Why should those who work hard and are successful not be suitably rewarded for their efforts? For government to step in and limit those rewards was unfair and high-handed, socialistic even. I mean, the horror. (Did I mention I was in college?)

Fast forward a few years.  I was out of college and working – paying my dues as a reporter at a local newspaper at a very low salary – dealing with not only my own financial struggles, living month to month, but also frequently reporting on the plights of others. This time, when I attempted to reread the book that I deemed in college to be one of the greatest novels ever, I couldn’t even finish it. I found it heartless, selfish and Darwinistic in the extreme.

Looking on it now, I can easily see it from both perspectives. The problem is that it’s virtually impossible to reconcile the two.

I suffer the same cognitive dissonance when it comes to the topics of drug pricing and patient access. As an industry observer, I’m well aware of the stats – the decades of R&D, clinical trials and regulatory processes to get a single drug to market; the costs that can climb to the hundreds of millions and are continuing to escalate; the discouraging failure rate; and the disappointing commercial sales of many drugs that actually make it to market – so I agree that it makes sense for innovators to have a chance to recoup their investments on the winners.

At the same time, as a health care consumer, I think it’s outrageous what we have to shell out just for basic coverage, and as a human being, I believe everyone should have access to the best treatments, regardless of who they are or where the live, without plunging their families into debt or bankrupting the system. In a perfect world, that’s how it would be.

But the world isn’t perfect. And the U.S. isn’t the only country wrestling with this particular issue. During the recent BIO Latin America conference, data from the Brazilian pharmaceutical market showed a similar trend of rising costs. In his presentation, Renato Faro, research, development and innovation manager at Bionovis in Brazil, pointed out that, in 2010, biologic drugs comprised a mere 3.7 percent of the total pharmaceuticals in the country but represented 32 percent of the total pharmaceutical costs.

At that rate, Faro said, “we’re going to break the country.”

It’s a policy conundrum for every country. The topic reared its head again during a luncheon discussion moderated by BIO President and CEO Jim Greenwood on building successful biotech infrastructures, with representatives from the U.S., Canada, Switzerland and France weighing in, particularly on the topic of intellectual property protection.

Greenwood actually summed it up pretty well: “If you’re the innovator trying to attract capital investment, it’s gold,” he said of IP protection. But for those in less economically advantageous positions, IP protection is “the enemy,” keeping drug prices high and lower-cost generics off the market.

In the U.S., policymakers opted to make IP protection a priority.

“We make that choice,” said Albert Keyack, U.S. IP attaché for South America, adding that “drugs will be quote-unquote expensive” simply because so few of the products make it through to market. Without allowing innovators to recoup their investments, capital for further biotech efforts would dry up.

“It’s like that old line about eating your seed corn,” Keyack added. “Where’s the next innovation going to come from?”

And that’s the question, isn’t it? The next innovation: What will it be and who will fund it?

For my part, I think the industry needs to focus on innovation, not only in terms of scientific advances, but even more on innovative ways of making drug development way more efficient. Many efforts already are under way, including adaptive trial designs, open access and data-sharing solutions, various technology platforms focused on speeding drug optimization and selection and the establishment of groups such as Trancelerate Biopharma Inc., which aims to simplify and accelerate development through the collaboration of its big pharma members.

As an industry observer, I applaud those efforts. As a health care consumer, I will concede they are a good start. But we need to see more. A lot more.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing